PRN · Profound Medical Corp. · Documents

Profound reported third-quarter revenue of $9.8 million, up 86%, and projects full-year 2026 revenue of at least $25 million. The Tulsa Pro install base reached 98 systems, and a distribution agreement with Cook Medical was signed last week.

Profound Medical Corp. announced a November 5, 2026 webinar at 3:00 p.m. ET featuring Montel Williams and recently installed the first TULSA-PRO system at a U.S. Department of Veterans Affairs facility.

Profound Medical Corp. announced five abstracts at the 15th Interventional MRI Symposium, including CAPTAIN results showing whole-gland TULSA patients were more than twice as likely to preserve erectile function and pad-free continence at six months.

On October 9, 2026, Profound Medical Corp. announced a co-education agreement with Telix Pharmaceuticals Limited to promote complementary PSMA-PET imaging and MRI-guided TULSA-PRO technologies. Profound is also developing PSMA-PET–MR image-fusion capabilities for a planned future TDC release.

Profound Medical Corp. expects preliminary revenue of $9.8 million to $10.0 million for the three months ended September 30, 2026, up approximately 85% to 89% year over year, with gross margin above 70%.

• Non-issuer's submission to jurisdiction and appointment of agent 4
• Shelf prospectus (NI 44-102) 2
• Other undertakings 1
• Final short form prospectus 1
• Other offering documents 2

• Shelf prospectus (NI 44-102) 1
• Qualification certificate 1
• Preliminary short form prospectus 1